The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.

Download and Print: Download Printer-friendly PDF Download data

Table 1.21

U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2016a Using Different Tumor Inclusion Criteriab

Site Sex 5-Year Limited Duration Prevalence 24-year Limited Duration Prevalence
1st Invasive
Tumor Everc		 1st Per Site in
Previous 24 Yearsd		 1st Per Site in
Previous 5 Yearse		 1st Invasive
Tumor Everc		 1st Per Site in
Previous 24 Yearsd
All Sites Both Sexes 4,618,309 4,788,249 5,268,178 13,238,684 13,725,579
Male 2,265,828 2,321,794 2,561,190 6,465,129 6,615,379
Female 2,352,481 2,466,455 2,706,988 6,773,555 7,110,200
Oral Cavity & Pharynx Both Sexes 116,614 137,601 142,958 285,683 322,983
Male 83,745 97,382 100,597 197,295 220,172
Female 32,869 40,219 42,361 88,388 102,811
Esophagus Both Sexes 21,742 27,114 27,273 37,573 44,872
Male 16,966 21,041 21,144 29,074 34,504
Female 4,776 6,073 6,129 8,499 10,368
Stomach Both Sexes 44,232 53,399 54,255 89,342 104,126
Male 25,922 31,498 31,907 51,076 59,722
Female 18,310 21,901 22,348 38,266 44,404
Colon & Rectum Both Sexes 384,576 444,429 452,381 1,077,905 1,211,974
Male 200,293 230,124 234,263 550,903 613,912
Female 184,283 214,305 218,118 527,002 598,062
Liver & Intrahepatic Bile Duct Both Sexes 48,352 56,128 56,342 70,556 80,067
Male 34,831 39,846 40,003 50,338 56,224
Female 13,521 16,282 16,339 20,218 23,843
Pancreas Both Sexes 43,231 53,929 54,044 57,753 70,735
Male 21,568 27,124 27,209 28,410 35,088
Female 21,663 26,805 26,835 29,343 35,647
Larynx Both Sexes 29,186 34,757 35,246 74,772 85,315
Male 23,886 28,382 28,773 61,289 69,580
Female 5,300 6,375 6,473 13,483 15,735
Lung & Bronchus Both Sexes 224,901 296,258 307,825 387,582 494,958
Male 102,077 135,269 139,706 170,233 217,057
Female 122,824 160,989 168,119 217,349 277,901
Melanoma of the Skin Both Sexes 291,465 340,956 359,793 897,922 1,003,650
Male 161,053 191,955 204,571 469,112 530,596
Female 130,412 149,001 155,222 428,810 473,054
Breast Female 915,040 1,009,922 1,069,620 2,862,940 3,112,731
Cervix Female 40,564 43,027 43,191 172,170 181,314
Corpus & Uterus, NOS Female 200,697 225,923 226,147 575,275 636,687
Ovaryf Female 62,449 71,655 71,737 158,048 180,026
Prostate Male 852,616 925,846 925,901 2,883,784 3,069,398
Testis Male 43,378 44,309 44,823 180,132 183,792
Urinary Bladder Both Sexes 201,203 254,235 260,387 528,898 631,413
Male 154,809 195,876 200,971 400,452 477,786
Female 46,394 58,359 59,416 128,446 153,627
Kidney & Renal Pelvis Both Sexes 168,243 204,952 208,257 406,205 479,439
Male 105,668 129,796 132,082 248,043 294,719
Female 62,575 75,156 76,175 158,162 184,720
Brain & Nervous System Both Sexes 44,838 48,165 48,639 121,093 126,388
Male 24,984 26,796 27,023 64,923 67,482
Female 19,854 21,369 21,616 56,170 58,906
Thyroid Both Sexes 203,126 229,536 230,264 587,959 644,571
Male 46,377 55,079 55,254 127,419 144,092
Female 156,749 174,457 175,010 460,540 500,479
Hodgkin Lymphoma Both Sexes 35,058 37,437 37,487 140,786 146,789
Male 19,459 20,890 20,914 74,193 77,233
Female 15,599 16,547 16,573 66,593 69,556
Non-Hodgkin Lymphoma Both Sexes 209,115 248,946 254,357 566,981 644,761
Male 113,015 135,137 138,113 300,944 342,069
Female 96,100 113,809 116,244 266,037 302,692
Myeloma Both Sexes 66,177 78,454 78,949 111,277 128,969
Male 36,691 44,371 44,700 61,269 72,052
Female 29,486 34,083 34,249 50,008 56,917
Leukemia Both Sexes 130,295 153,253 153,837 336,170 376,508
Male 76,451 90,192 90,566 193,982 217,145
Female 53,844 63,061 63,271 142,188 159,363
Acute Lymphocytic Leukemia Both Sexes 19,515 20,277 20,277 69,109 70,308
Male 10,797 11,203 11,203 38,607 39,179
Female 8,718 9,074 9,074 30,502 31,129
Childhood (Ages 0-19) Both Sexes 67,096 67,129 67,682 264,287 264,940
Male 35,300 35,299 35,549 139,152 139,459
Female 31,796 31,830 32,133 125,135 125,481
Kaposi Sarcoma Both Sexes 7,567 8,281 8,281 32,104 33,825
Male 6,918 7,549 7,549 30,486 32,021
Female 649 732 732 1,618 1,804
Mesothelioma Both Sexes 3,199 4,257 4,257 4,536 5,767
Male 2,203 2,983 2,983 2,834 3,687
Female 996 1,274 1,274 1,702 2,080

Footnotes:

a U.S. 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 registries (not including the Alaska Natives Registry) and 1/1/2016 U.S. population estimates based on the average of 2015 and 2016 population estimates from the U.S. Bureau of the Census.

b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion which are listed in footnotes (c) to (e).

c First invasive tumor ever. Referred to as method (c) in Example below.

d First invasive tumor for each cancer site diagnosed during the previous 24 years (1992-2015). All sites is treated as a separate cancer "site". Referred to as method (d) in Example below.

e First invasive tumor for each cancer site diagnosed during the previous 5 years (2011-2015). All sites is treated as a separate cancer "site". Referred to as method (e) in Example below.

Example: Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.
In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 24-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2016.
In method (d) the 1981 melanoma is counted for the melanoma and all sites 24-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 24-year limited duration prevalence.
In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.